| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1046227163 |
| P356 | DOI | 10.1097/GIM.0B013E3181B13A6C |
| P932 | PMC publication ID | 2936269 |
| P698 | PubMed publication ID | 19617843 |
| P50 | author | Francis Collins | Q336658 |
| Centers for Disease Control and Prevention | Q583725 | ||
| George M. Church | Q3298995 | ||
| John Ioannidis | Q6251482 | ||
| Kári Stefánsson | Q6453246 | ||
| Robert C. Green | Q7342606 | ||
| Sharon F. Terry | Q7490049 | ||
| Sharon L R Kardia | Q88218091 | ||
| Philip Greenland | Q93019727 | ||
| Ralph J. Coates | Q124654554 | ||
| Paul L. Kimmel | Q130390505 | ||
| Kenneth Offit | Q20732365 | ||
| Michael S. Lauer | Q27205541 | ||
| Stephen Chanock | Q27662321 | ||
| Jay M. Bernhardt | Q43836495 | ||
| Cecile Janssens | Q58477081 | ||
| Barry R. Davis | Q64684716 | ||
| Muin J. Khoury | Q64746271 | ||
| Marta Gwinn | Q64748945 | ||
| Sheri D Schully | Q64749037 | ||
| Jeffrey Gulcher | Q66823431 | ||
| Jianfeng Xu | Q67190177 | ||
| Rebekah Rasooly | Q38155014 | ||
| P2093 | author name string | Mark H Greene | |
| Mitchell H Gail | |||
| John S Witte | |||
| Geoffrey S Ginsburg | |||
| Michele Cargill | |||
| W Gregory Feero | |||
| Gregory J Downing | |||
| Steven M Teutsch | |||
| J Scott Roberts | |||
| David F Ransohoff | |||
| Colleen M McBride | |||
| Susan Friedman | |||
| Angela Trepanier | |||
| Robert T Croyle | |||
| Kathy L Hudson | |||
| Denise G Simons-Morton | |||
| Amy Duross | |||
| Amy M Miller | |||
| Andro Hsu | |||
| Kay L Wanke | |||
| P2860 | cites work | Point: genetic risk feedback for common disease time to test the waters | Q81251130 |
| Counterpoint: genetic risk feedback for common disease time to test the waters | Q81251134 | ||
| Cohort studies and the genetics of complex disease | Q83106332 | ||
| Personalized genetic prediction: too limited, too expensive, or too soon? | Q83203055 | ||
| Update on the methods of the U.S. Preventive Services Task Force: insufficient evidence | Q83288867 | ||
| When is measuring sensitivity and specificity sufficient to evaluate a diagnostic test, and when do we need randomized trials? | Q83930135 | ||
| Interpretation of genetic association studies: markers with replicated highly significant odds ratios may be poor classifiers | Q21563322 | ||
| Meta-analysis in genome-wide association studies | Q24273398 | ||
| Genome-wide association studies for complex traits: consensus, uncertainty and challenges | Q24550632 | ||
| Rare independent mutations in renal salt handling genes contribute to blood pressure variation | Q24627187 | ||
| Blazing a trail: a public health research agenda in genomics and chronic disease | Q25257780 | ||
| Letting the genome out of the bottle--will we get our wish? | Q28264215 | ||
| Size matters: just how big is BIG?: Quantifying realistic sample size requirements for human genome epidemiology | Q28755468 | ||
| General cardiovascular risk profile for use in primary care: the Framingham Heart Study | Q29614189 | ||
| Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond | Q29614697 | ||
| A HapMap harvest of insights into the genetics of common disease | Q29614875 | ||
| Genetic mapping in human disease | Q29614943 | ||
| Pharmacogenomics: candidate gene identification, functional validation and mechanisms | Q33375573 | ||
| Estimation of the warfarin dose with clinical and pharmacogenetic data | Q33410725 | ||
| A health services research agenda for cellular, molecular and genomic technologies in cancer care | Q33749983 | ||
| Integrating the predictiveness of a marker with its performance as a classifier | Q34129175 | ||
| Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels | Q34478587 | ||
| Risky communication: pitfalls in counseling about risk, and how to avoid them | Q80251479 | ||
| The case for a global human genome epidemiology initiative | Q80800985 | ||
| The genome gets personal--almost | Q80893890 | ||
| Genomic profiles for disease risk: predictive or premature? | Q80893894 | ||
| A meta-analysis of the effect of mediated health communication campaigns on behavior change in the United States | Q40532001 | ||
| An unwelcome side effect of direct-to-consumer personal genome testing: raiding the medical commons | Q42091906 | ||
| Gauging the performance of SNPs, biomarkers, and clinical factors for predicting risk of breast cancer | Q42791172 | ||
| Pharmacogenetics--tailoring treatment for the outliers | Q46116659 | ||
| Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation | Q46157298 | ||
| Pharmacogenomics--ready for prime time? | Q46716977 | ||
| The feasibility of online genetic testing for lung cancer susceptibility: uptake of a web-based protocol and decision outcomes | Q46747840 | ||
| Predictors of attrition and weight loss in an adolescent weight control program | Q47241118 | ||
| Developing a center for comparative effectiveness information | Q47586561 | ||
| Evaluating the utility of personal genomic information | Q47593006 | ||
| Genetic susceptibility testing versus family history-based risk assessment: Impact on perceived risk of Alzheimer disease | Q49141542 | ||
| The evidence dilemma in genomic medicine | Q50769689 | ||
| Incorporating biomarkers of exposure and genetic susceptibility into smoking cessation treatment: effects on smoking-related cognitions, emotions, and behavior change | Q51108076 | ||
| A navigator for human genome epidemiology | Q51895975 | ||
| Effects of attributing serious mental illnesses to genetic causes on orientations to treatment | Q51920543 | ||
| What is the clinical utility of genetic testing? | Q52012351 | ||
| Time to check CHEK2 in families with breast cancer? | Q55047407 | ||
| Misdirected precaution | Q57261722 | ||
| Turning the Pump Handle: Evolving Methods for Integrating the Evidence on Gene-Disease Association | Q57542900 | ||
| Beyond odds ratios — communicating disease risk based on genetic profiles | Q58047301 | ||
| Psychological impact of genetic testing for familial hypercholesterolemia within a previously aware population: A randomized controlled trial | Q60697564 | ||
| Difficulty in losing weight by behavioral intervention for women with Trp64Arg polymorphism of the beta3-adrenergic receptor gene | Q73807082 | ||
| Genome-based prediction of common diseases: advances and prospects | Q34851798 | ||
| Assessing the value of risk predictions by using risk stratification tables | Q34969023 | ||
| Population screening in the age of genomic medicine | Q35037759 | ||
| Genetic testing for Alzheimer's disease and its impact on insurance purchasing behavior | Q35567406 | ||
| Simple tools for understanding risks: from innumeracy to insight | Q36037510 | ||
| On criteria for evaluating models of absolute risk | Q36072628 | ||
| Pharmacogenetics and pharmacogenomics: development, science, and translation | Q36583761 | ||
| A critical appraisal of the scientific basis of commercial genomic profiles used to assess health risks and personalize health interventions | Q36719129 | ||
| Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study | Q36790111 | ||
| Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk | Q36858843 | ||
| Putting science over supposition in the arena of personalized genomics | Q36865829 | ||
| Assessing the combined impact of 18 common genetic variants of modest effect sizes on type 2 diabetes risk | Q36943793 | ||
| Assessment of cumulative evidence on genetic associations: interim guidelines | Q36952959 | ||
| The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? | Q37029751 | ||
| Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. | Q37036119 | ||
| Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors | Q37037058 | ||
| Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3. | Q37069329 | ||
| Psychosocial issues in genetic testing for familial adenomatous polyposis: a review of the literature. | Q37211096 | ||
| The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group | Q37277889 | ||
| Looking to the future of new media in health marketing: deriving propositions based on traditional theories. | Q37303272 | ||
| Pharmacogenomic dosing of warfarin: ready or not? | Q37334317 | ||
| Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? | Q37345971 | ||
| Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives | Q37345978 | ||
| Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer? | Q37345983 | ||
| The genomic applications in practice and prevention network | Q37345987 | ||
| Impact of adding a single allele in the 9p21 locus to traditional risk factors on reclassification of coronary heart disease risk and implications for lipid-modifying therapy in the Atherosclerosis Risk in Communities study | Q37408982 | ||
| Psychosocial aspects of DNA testing for hereditary hemochromatosis in at-risk individuals: a systematic review | Q37421773 | ||
| Disclosure of APOE genotype for risk of Alzheimer's disease | Q37423417 | ||
| Predicting type 2 diabetes based on polymorphisms from genome-wide association studies: a population-based study | Q40060574 | ||
| Chromosome 9p21.3 coronary heart disease locus genotype and prospective risk of CHD in healthy middle-aged men. | Q40126925 | ||
| The impact of genotype frequencies on the clinical validity of genomic profiling for predicting common chronic diseases | Q40182769 | ||
| Using wireless handheld computers and tailored text messaging to reduce negative consequences of drinking alcohol. | Q40203757 | ||
| Use and misuse of the receiver operating characteristic curve in risk prediction | Q40241086 | ||
| Self-regulation and the behavioural response to DNA risk information: a theoretical analysis and framework for future research | Q40389106 | ||
| Who seeks genetic susceptibility testing for Alzheimer's disease? Findings from a multisite, randomized clinical trial | Q40494480 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | personal genomics | Q7170583 |
| workshop | Q27556165 | ||
| P1104 | number of pages | 9 | |
| P304 | page(s) | 559-567 | |
| P577 | publication date | 2009-08-01 | |
| P1433 | published in | Genetics in Medicine | Q15765508 |
| P1476 | title | The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop | |
| P478 | volume | 11 |
| Q36595655 | "Is it really worth it to get tested?": primary care patients' impressions of predictive SNP testing for colon cancer |
| Q34046262 | A community standard for immunogenomic data reporting and analysis: proposal for a STrengthening the REporting of Immunogenomic Studies statement |
| Q33915049 | A compendium of genome-wide associations for cancer: critical synopsis and reappraisal |
| Q35854145 | A formal risk-benefit framework for genomic tests: Facilitating the appropriate translation of genomics into clinical practice |
| Q33728176 | A survey of UK public interest in internet-based personal genome testing |
| Q28396443 | An Empirical Evaluation of normalization Methods for MicroRNA Arrays in a Liposarcoma Study |
| Q34344701 | An epidemiological perspective on the future of direct-to-consumer personal genome testing |
| Q57990011 | Assessing the Pedagogical Goals of Self-Testing in Evaluating the Consultation Needs of Different Student Populations |
| Q34194916 | Attitudes on DNA ancestry tests |
| Q28390595 | Beyond Base Pairs to Bedside: A Population Perspective on How Genomics Can Improve Health |
| Q36678417 | Bridging the Communication Divide: A Role for Health Psychology in the Genomic Era. |
| Q33717364 | Cancer screening and genetics: a tale of two paradigms |
| Q24289209 | Cardiovascular epidemiology in a changing world--challenges to investigators and the National Heart, Lung, and Blood Institute |
| Q37571916 | Characteristics associated with informed consent for genetic studies in the ACCORD trial |
| Q33817900 | Clinical and public health implications of emerging genetic technologies |
| Q36800565 | Clinical decision support for genetically guided personalized medicine: a systematic review |
| Q35423118 | Commentary: Children and Predictive Genomic Testing: Disease Prevention, Research Protection, and Our Future |
| Q84521379 | Community standards: a new policy to ensure consistency and transparency in immunogenomics |
| Q28395074 | Concerns about unintended negative consequences of informing the public about multifactorial risks may be premature for young adult smokers |
| Q45924134 | Considerations for the impact of personal genome information: a study of genomic profiling among genetics and genomics professionals. |
| Q37778382 | Consumers' Views of Direct-to-Consumer Genetic Information |
| Q38424242 | Current Priorities for Public Health Practice in Addressing the Role of Human Genomics in Improving Population Health |
| Q50691856 | Dealing with the evidence dilemma in genomics and personalized medicine |
| Q36772851 | Defining Ourselves: Personal Bioinformation as a Tool of Narrative Self-Conception |
| Q36898879 | Development and evaluation of a genetic risk score for obesity |
| Q34657518 | Development of a communication protocol for telephone disclosure of genetic test results for cancer predisposition |
| Q37797761 | Diagnosing Hereditary Colorectal Cancer |
| Q30474378 | Direct-to-Consumer Genetic and Genomic Testing: Preparing Nurse Practitioners for Genomic Healthcare |
| Q36884571 | Direct-to-consumer genomic testing from the perspective of the health professional: a systematic review of the literature. |
| Q37143257 | Does a medical history of hypertension influence disclosing genetic testing results of the risk for salt-sensitive hypertension, in primary care? |
| Q34129889 | Early identification of cardiovascular risk using genomics and proteomics |
| Q52560326 | Evaluation of a decision aid for incidental genomic results, the Genomics ADvISER: protocol for a mixed methods randomised controlled trial |
| Q56780467 | Evaluation of genetic tests for susceptibility to common complex diseases: why, when and how? |
| Q37786243 | Evaluation of the Validity and Utility of Genetic Testing for Rare Diseases |
| Q35945361 | Explaining, not just predicting, drives interest in personal genomics |
| Q37412229 | Field-wide meta-analyses of observational associations can map selective availability of risk factors and the impact of model specifications |
| Q22122198 | Finding the missing heritability of complex diseases |
| Q34286705 | From prenatal genomic diagnosis to fetal personalized medicine: progress and challenges |
| Q49841808 | From public health genomics to precision public health: a 20-year journey |
| Q26830861 | Genetic data and electronic health records: a discussion of ethical, logistical and technological considerations |
| Q53120041 | Genetic research and aboriginal and Torres Strait Islander Australians |
| Q36061256 | Genetic testing behavior and reporting patterns in electronic medical records for physicians trained in a primary care specialty or subspecialty |
| Q34571172 | Genetics and primary care: where are we headed? |
| Q33821365 | Genetics of focal segmental glomerulosclerosis and human immunodeficiency virus-associated collapsing glomerulopathy: the role of MYH9 genetic variation |
| Q34971361 | Genome Medicine: past, present and future |
| Q34193988 | Genome-wide association studies of cancer |
| Q35944422 | Genomes, populations and diseases: ethnic genomics and personalized medicine |
| Q38114005 | Genomic Medicine: A Decade of Successes, Challenges, and Opportunities |
| Q36286855 | Genomic newborn screening: public health policy considerations and recommendations |
| Q34094016 | Genotype-informed estimation of risk of coronary heart disease based on genome-wide association data linked to the electronic medical record |
| Q43879300 | Germline single nucleotide polymorphisms associated with response of urothelial carcinoma to platinum-based therapy: the role of the host |
| Q39276157 | Guidelines for return of research results from pediatric genomic studies: deliberations of the Boston Children's Hospital Gene Partnership Informed Cohort Oversight Board |
| Q34515586 | Health System Implications of Direct-to-Consumer Personal Genome Testing |
| Q35907523 | Health care providers and direct-to-consumer access and advertising of genetic testing in the United States |
| Q34327946 | How can polygenic inheritance be used in population screening for common diseases? |
| Q34302008 | How the electronic health record will change the future of health care |
| Q85006329 | Illusions of scientific legitimacy: misrepresented science in the direct-to-consumer genetic-testing marketplace |
| Q35248032 | Impact of Direct-to-Consumer Predictive Genomic Testing on Risk Perception and Worry Among Patients Receiving Routine Care in a Preventive Health Clinic |
| Q33654267 | Implementing an Internet-Delivered Skin Cancer Genetic Testing Intervention to Improve Sun Protection Behavior in a Diverse Population: Protocol for a Randomized Controlled Trial |
| Q37981029 | Inclusion and Exclusion in Nutrigenetics Clinical Research: Ethical and Scientific Challenges |
| Q35576352 | Integrating genetic studies of nicotine addiction into public health practice: stakeholder views on challenges, barriers and opportunities |
| Q35157620 | Knowledge and attitudes to personal genomics testing for complex diseases among Nigerians |
| Q37800175 | Mendelian genetics of rare—and not so rare—cancers |
| Q98226260 | Molecular Profiling of Advanced Malignancies: A Community Oncology Network Experience and Review of Literature |
| Q35576348 | Motivations and Perceptions of Early Adopters of Personalized Genomics: Perspectives from Research Participants |
| Q46691615 | Multigenic condition risk assessment in direct-to-consumer genomic services |
| Q36352858 | Multilevel research and the challenges of implementing genomic medicine |
| Q37651413 | Next generation DNA sequencing and the future of genomic medicine |
| Q38637859 | Obesity, More than a 'Cosmetic' Problem. Current Knowledge and Future Prospects of Human Obesity Genetics |
| Q33983987 | Only connect: personal genomics and the future of American medicine |
| Q38037294 | Opportunities and challenges associated with clinical diagnostic genome sequencing: a report of the Association for Molecular Pathology. |
| Q34071625 | Overview of a chemoresponse assay in ovarian cancer |
| Q36068717 | Parents' perceptions of the usefulness of chromosomal microarray analysis for children with autism spectrum disorders |
| Q33815053 | Parents' preferences for return of results in pediatric genomic research |
| Q40533108 | Participant Satisfaction With a Preference-Setting Tool for the Return of Individual Research Results in Pediatric Genomic Research. |
| Q33932189 | Personal genome testing: test characteristics to clarify the discourse on ethical, legal and societal issues |
| Q37716422 | Personal genomic information management and personalized medicine: challenges, current solutions, and roles of HIM professionals |
| Q36158668 | Personal utility and genomic information: look before you leap |
| Q45299444 | Personal utility in genomic testing: is there such a thing? |
| Q35082635 | Personalized medicine: new genomics, old lessons |
| Q26853274 | Perspectives on pharmacogenomics of antiretroviral medications and HIV-associated comorbidities |
| Q35291344 | Population Sciences, Translational Research, and the Opportunities and Challenges for Genomics to Reduce the Burden of Cancer in the 21st Century |
| Q35011179 | Primary care patient willingness for genetic testing for salt-sensitive hypertension: a cross sectional study |
| Q37171548 | Primary care patients’ views and decisions about, experience of and reactions to direct-to-consumer genetic testing: a longitudinal study |
| Q53840231 | Providing Unrestricted Access to Prenatal Testing Does Not Translate to Enhanced Autonomy |
| Q41889955 | Public awareness and use of direct-to-consumer personal genomic tests from four state population-based surveys, and implications for clinical and public health practice |
| Q54645897 | Public opinion on policy issues in genetics and genomics. |
| Q34131978 | Regional differences in awareness and attitudes regarding genetic testing for disease risk and ancestry |
| Q57314152 | Regulating direct-to-consumer genetic tests: What is all the fuss about? |
| Q92380938 | Research participants' experiences with return of genetic research results and preferences for web-based alternatives |
| Q41526681 | Review of the Reported Measures of Clinical Validity and Clinical Utility as Arguments for the Implementation of Pharmacogenetic Testing: A Case Study of Statin-Induced Muscle Toxicity |
| Q34444807 | Role of genomics in cardiovascular medicine |
| Q47419984 | Size of the direct-to-consumer genomic testing market |
| Q35868703 | Skin Cancer Concerns and Genetic Risk Information-Seeking in Primary Care |
| Q46937044 | Ten years later, still “gene in a haystack?”* |
| Q34082166 | The Emergence of Translational Epidemiology: From Scientific Discovery to Population Health Impact |
| Q37412563 | The Informed Cohort Oversight Board: From Values to Architecture |
| Q37148886 | The beliefs, motivations, and expectations of parents who have enrolled their children in a genetic biorepository |
| Q45304654 | The development of a preference-setting model for the return of individual genomic research results |
| Q50683723 | The incorporation of predictive genomic testing into genetic counseling programs |
| Q84152644 | The prospect of genome-guided preventive medicine: a need and opportunity for genetic counselors |
| Q34121303 | The rules remain the same for genomic medicine: the case against "reverse genetic exceptionalism". |
| Q33722761 | Translating colorectal cancer prevention through the guanylyl cyclase C signaling axis |
| Q34515568 | Translational research in cancer genetics: the road less traveled |
| Q49387154 | U.S. Physician-Scientist Workforce in the 21st Century: Recommendations to Attract and Sustain the Pipeline |
| Q28392540 | Using lifetime risk estimates in personal genomic profiles: estimation of uncertainty |
| Q37875809 | Voting with their Mice: Personal Genome Testing and the “Participatory Turn” in Disease Research |
| Q58169409 | Walking the tightrope: Expectations and standards in personal genomics |
Search more.